Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1985-4-23
|
| pubmed:abstractText |
An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81%) obtained a complete remission. Although the complete remission rate was high for patients with both null- and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (greater than 306 weeks) than patients with T-cell disease (62 weeks). The median survival by life-table analysis for the 48 patients is projected to be greater than 310 weeks, and five patients have finished the 3-year treatment program and have been off therapy for 1-3 years without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. Most importantly, this treatment protocol identifies by therapeutic response a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and who appear, in substantial proportion, to be potentially curable.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Asparaginase,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0361-5960
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
69
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
153-60
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3855697-Actuarial Analysis,
pubmed-meshheading:3855697-Acute Disease,
pubmed-meshheading:3855697-Adolescent,
pubmed-meshheading:3855697-Adult,
pubmed-meshheading:3855697-Aged,
pubmed-meshheading:3855697-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3855697-Asparaginase,
pubmed-meshheading:3855697-Bone Marrow,
pubmed-meshheading:3855697-Combined Modality Therapy,
pubmed-meshheading:3855697-Doxorubicin,
pubmed-meshheading:3855697-Female,
pubmed-meshheading:3855697-Humans,
pubmed-meshheading:3855697-Leukemia, Lymphoid,
pubmed-meshheading:3855697-Male,
pubmed-meshheading:3855697-Methotrexate,
pubmed-meshheading:3855697-Middle Aged,
pubmed-meshheading:3855697-Nervous System Neoplasms,
pubmed-meshheading:3855697-Prednisone,
pubmed-meshheading:3855697-Prognosis,
pubmed-meshheading:3855697-Recurrence,
pubmed-meshheading:3855697-Vincristine
|
| pubmed:year |
1985
|
| pubmed:articleTitle |
Long-term relapse-free survival in adult acute lymphoblastic leukemia.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|